Literature DB >> 30406892

[Cancer screening in Germany: availability and participation].

Anne Starker1, Nina Buttmann-Schweiger2, Laura Krause2, Benjamin Barnes2, Klaus Kraywinkel2, Christine Holmberg3.   

Abstract

In Germany, approximately 227,000 women and 249,000 men developed cancer in 2014, and nearly 223,000 patients died from the disease that year. Many cancers are curable or have a very good prognosis when they are diagnosed at an early stage. This is where the concept of early detection examinations comes into play.This article describes the current conditions of and participation in examinations for the early detection of cervical, breast, skin, prostate, and colon cancer as provided by Germany's statutory health services. Participation was derived from claims data from the statutory health insurance system as well as from Germany's mammography screening program (MSP). The survey "German Health Update" (GEDA 2014/2015-EHIS) served as an additional data source. According to the claims data and considering the intended intervals, participation quotas among insured persons who are entitled to participate lie between 16% (colonoscopy) and 48% (Pap test). In 2015, 51.5% of invited women participated in the MSP. The results according to self-reports of the GEDA survey lie in part substantially higher. The results according to the claims data, the MSP, as well as the self-reports suggest that a large part of the population utilizes the examinations. Colon and cervical cancer examinations will be expanded as organized and quality-assured early detection programs with regular invitations and information on benefits and risks. These efforts should contribute to reaching eligible people who have thus far not participated.

Entities:  

Keywords:  Cancer screening; Germany; Health monitoring; Prevention; Utilization

Mesh:

Year:  2018        PMID: 30406892     DOI: 10.1007/s00103-018-2842-8

Source DB:  PubMed          Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz        ISSN: 1436-9990            Impact factor:   1.513


  8 in total

Review 1.  [Intelligent early prostate cancer detection in 2021: more benefit than harm].

Authors:  N Westhoff; J von Hardenberg; M-S Michel
Journal:  Urologe A       Date:  2021-04-21       Impact factor: 0.639

2.  Prevalence of abnormal Pap smear results in inflammatory bowel disease: a prospective study.

Authors:  Andrea Brunner; Wolfgang Kruis; Birgid Schömig-Markiefka; Julia Morgenstern; Marianne Engels; Reinhard Büttner; Dirk Michael Forner
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-03       Impact factor: 4.322

3.  Intention for Screening Colonoscopy among Previous Non-Participants: Results of a Representative Cross-Sectional Study in Germany.

Authors:  Anne Starker; Franziska Prütz; Susanne Jordan
Journal:  Int J Environ Res Public Health       Date:  2021-04-14       Impact factor: 3.390

4.  Utilisation of outpatient medical services in Germany - Results from GEDA 2019/2020-EHIS.

Authors:  Franziska Prütz; Alexander Rommel; Julia Thom; Yong Du; Giselle Sarganas; Anne Starker
Journal:  J Health Monit       Date:  2021-09-15

5.  30 years after the fall of the Berlin Wall: Regional health differences in Germany.

Authors:  Thomas Lampert; Stephan Müters; Benjamin Kuntz; Stefan Dahm; Enno Nowossadeck
Journal:  J Health Monit       Date:  2019-11-01

6.  Socioeconomic deprivation and cancer survival in a metropolitan area: An analysis of cancer registry data from Hamburg, Germany.

Authors:  Lina Jansen; Cynthia Erb; Alice Nennecke; Isabelle Finke; Ron Pritzkuleit; Bernd Holleczek; Hermann Brenner
Journal:  Lancet Reg Health Eur       Date:  2021-02-26

7.  Gynaecology and general practitioner services utilisation by women in the age group 50 years and older.

Authors:  Laura Krause; Lorena Dini; Franziska Prütz
Journal:  J Health Monit       Date:  2020-06-30

8.  Evaluation of prevention behaviour and its influencing factors with respect to cancer screening.

Authors:  Adam Dawid; Christoph Borzikowsky; Sandra Freitag-Wolf; Sabine Herlitzius; Hans-Jürgen Wenz; Jörg Wiltfang; Katrin Hertrampf
Journal:  J Cancer Res Clin Oncol       Date:  2022-03-07       Impact factor: 4.322

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.